Biotherapix

Biotherapix Molecular Medicines is a Spanish biotechnology company and a subsidiary of the Genetrix Group, specializing in the discovery and development of human monoclonal antibodies and derived molecules. The company focuses on treating infectious, inflammatory, and degenerative diseases, with a particular emphasis on high-affinity biological molecules. Its pipeline includes chemokine receptor antagonists, known as Diakinas, and neutralizing antibodies for HIV-1. Biotherapix leverages a proprietary platform for the generation and screening of human antibodies to address unmet medical needs in areas such as rare diseases and neurodegeneration. Headquartered in Madrid, the company has historically collaborated with academic institutions and other biotech firms like VivaCell to advance its therapeutic candidates.